糖尿病デバイスの世界市場：2025年～2033年

糖尿病デバイスの世界市場は、2024年に334億米ドルに達し、2033年には648億米ドルに達し、予測期間2025年のCAGRは7.7%で成長すると予測されています。

糖尿病有病率の上昇と新規製品の上市は、糖尿病デバイスの市場規模の成長を大きく後押ししており、予測期間中も市場を牽引すると予想されます。糖尿病の世界の有病率は過去数十年間で劇的に上昇しています。例えば、国際糖尿病連合によると、2021年には5億3,660万人の成人（20～79歳）が糖尿病、すなわち10人に1人の割合で生活しています。この数は2030年までに6億4,280万人、2045年までに7億8,370万人に増加すると予測されています。成人の糖尿病患者の4人に3人以上が低・中所得国に住んでいます。このような有病率の増加は、糖尿病デバイスの緊急ニーズを浮き彫りにしています。

糖尿病デバイス市場における新たな製品投入は、糖尿病管理をより効率的で個別化された身近なものにし、革命をもたらしつつあります。これらの技術革新は、持続的グルコースモニタリングとインスリン投与システムを、より使いやすく、正確で、費用対効果の高いものにしています。先進的なCGMシステムの発売は、糖尿病患者の病状管理方法を大きく変えました。これらの装置は血糖値を継続的に測定し、リアルタイムのデータを提供し、頻繁に指を刺す検査の必要性を減らしています。

例えば、2024年9月、Senseonics Holdings, Inc.とAscensia Diabetes Careは、18歳以上の1型および2型糖尿病患者向けの次世代CGMシステムEversense 365について、米国食品医薬品局（FDA）の認可を取得しました。エバーセンス365は世界初の1年CGMシステムであり、糖尿病技術と管理における重要なブレークスルーとなります。

スマートインスリンペン、CGM、インスリンポンプなどの新しい製品の発売は、糖尿病管理の利便性と精度を向上させています。これにより患者のアドヒアランスが向上し、長期的な疾病管理が改善されるため、これらの製品に対する需要が高まっています。例えば、2024年9月、Embecta Corp.は、独自の使い捨てインスリンデリバリーシステムについて、米国食品医薬品局（FDA）から510（k）認可を取得しました。このシステムは、1型（T1D）と2型（T2D）の両方を含む糖尿病の管理にインスリンを必要とする成人に適応され、T2D患者とその医療従事者からのフィードバックに基づいた300単位のインスリンリザーバーを備えたチューブレスパッチポンプデザインを含みます。

糖尿病デバイスの高価格は、市場の成長を妨げる大きな要因です。この業界における技術の進歩により、より正確で効率的、かつ使いやすい機器が開発された一方で、価格が高いため、特に開発途上国や低所得者層にとっては利用しにくくなっています。例えば、米国国立衛生研究所によると、CGMのコストはデバイスのコストを加えると大幅に相殺され、12ヵ月間のフォローアップ期間中の平均は4,431ドルであるのに対し、血糖モニターは319ドルです。

持続血糖モニター（CGM）、インスリンポンプ、クローズドループシステムなどの機器は、初期費用が高額になる傾向があり、多くの糖尿病患者には手が届きません。例えば、Dexcom G6トランスミッターは、90日間使用する場合、保険なしで366ドルかかります。Dexcom G6 CGMシステムは、非スマートフォンユーザー用の受信機（540ドル）と互換性のある携帯電話を除くと、年間約8,000ドルの自己負担となります。コストが高いため、特に中低所得国では、CGMシステムの導入が制限されています。この高価格が、CGMとインスリンポンプの普及の大きな障壁となっています。

当レポートでは、世界の糖尿病デバイス市場について調査し、市場の概要とともに、製品タイプ別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブの洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界の展望

• 市場のリーダーと先駆者
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 糖尿病デバイス市場、製品タイプ別

• 血糖値モニタリング装置
  • 持続血糖測定装置
  • 自己監視デバイス
• インスリン投与装置

第6章 糖尿病デバイス市場、エンドユーザー別

• 病院
• 専門クリニック
• 在宅医療
• 診断センター
• その他

第7章 糖尿病デバイス市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第8章 競合情勢と市場ポジショニング

第9章 企業プロファイル

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Medtronic plc
• Terumo Corporation
• B. Braun SE
• Insulet Corporation
• Nipro Corporation
• Johnson &Johnson Services, Inc.
• Senseonics, Inc.
• Tandem Diabetes Care, Inc.

第10章 仮定と調査手法

第11章 付録

The global diabetes devices market reached US$ 33.4 billion in 2024 and is expected to reach US$ 64.8 billion by 2033, growing at a CAGR of 7.7% during the forecast period 2025-2033.

Diabetes devices are the medical devices used to manage and monitor diabetes. These devices help individuals with diabetes control their blood glucose levels, deliver insulin and improve overall management of the condition, thus reducing the risks of complications such as cardiovascular diseases, kidney failure and neuropathy. The main functions diabetes devices serve include monitoring blood glucose levels, administering insulin or other medications, and providing continuous real-time data for more informed decision-making.

The diabetes devices market has seen significant growth in recent years, driven by the increasing prevalence of diabetes worldwide, technological advancements in diabetes devices and rising awareness about the importance of managing the disease. Advancements especially in continuous glucose monitoring devices have seen a surge in demand as they allow patients to continuously track their blood glucose levels in real time. These rising advancements expected to boost the market demand.

"Abbott, Tandem Diabetes, and Sequel lead breakthroughs in continuous glucose monitoring and insulin delivery systems as global diabetes devices market continues to surge"

Recent FDA Approvals and Innovations

As the demand for cutting-edge diabetes management solutions increases, several major companies are setting new standards with groundbreaking products:

• Abbott Receives FDA Clearance (June, 2024): Abbott has received FDA clearance for two new over-the-counter continuous glucose monitoring systems, marking a significant step in making diabetes management more accessible to the public.
• Tandem Mobi Insulin Pump Compatibility (May, 2024): Tandem Diabetes Care's Tandem Mobi Insulin Pump is now compatible with Dexcom G7 CGM, offering enhanced real-time monitoring and insulin delivery to improve patient control.
• FDA Approves Hybrid Closed-Loop Insulin Delivery App (May, 2024): CamDiab's innovative app has gained FDA approval for hybrid closed-loop insulin delivery, revolutionizing diabetes care by automating insulin adjustments based on real-time glucose data.
• Sequel's twiist Automated Insulin Delivery System (March, 2024): Sequel has received FDA 510(k) clearance for its twiist automated insulin delivery system, bringing more efficient insulin delivery technology to patients.
• FDA Clears First Over-the-Counter Continuous Glucose Monitor (March, 2024): A groundbreaking achievement as the first over-the-counter continuous glucose monitor received FDA clearance, giving individuals greater autonomy in managing their blood glucose levels.
• Tandem Mobi Launch (February 2024): Tandem Diabetes Care introduces Tandem Mobi, the world's smallest and most durable automated insulin delivery system, setting a new standard in patient-friendly insulin management.

Market Dynamics: Drivers & Restraints

Rising prevalence of diabetes and novel product launches

The rising prevalence of diabetes and novel product launches is significantly driving the growth of the diabetes devices market and is expected to drive the market over the forecast period. The global prevalence of diabetes has risen dramatically over the past few decades. For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. This escalating prevalence highlights the urgent need for diabetes devices.

Novel product launches in the diabetes devices market are revolutionizing diabetes management, making it more efficient, personalized and accessible. These innovations are making continuous glucose monitoring and insulin delivery systems more user-friendly, accurate and cost-effective. The launch of advanced CGM systems has significantly changed how patients with diabetes manage their condition. These devices continuously measure blood glucose levels, offering real-time data and reducing the need for frequent finger-prick tests.

For instance, in September 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care, received the U.S. Food and Drug Administration (FDA) clearence for the next-generation Eversense 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. Eversense 365 is the world's first One Year CGM system, representing a significant breakthrough in diabetes technology and management.

Novel product launches such as smart insulin pens, CGMs and insulin pumps are offering greater convenience and accuracy in managing diabetes. This increases patient adherence and improves long-term disease management, leading to higher demand for these products. For instance, in September 2024, Embecta Corp. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system, indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers.

High cost of the devices

The high cost of diabetes devices is a significant factor that is hampering the growth of the market. While technological advancements in the industry have led to more accurate, efficient and user-friendly devices, their high price limits accessibility, particularly in developing countries or for low-income populations. For instance, according to the National Institute of Health, the costs with CGM are substantially offset if device costs are added, with an average of $4,431 during the 12-month follow-up versus $319 for blood glucose monitor.

Devices such as Continuous Glucose Monitors (CGMs), insulin pumps and closed-loop systems tend to have high upfront costs, making them out of reach for many diabetes patients. For instance, a Dexcom G6 transmitter costs $366 without insurance for one device that lasts 90 days. The Dexcom G6 CGM system can cost around $8,000 annually out-of-pocket, excluding a receiver for non-smartphone users ($540) and a compatible phone. The high cost limits the adoption of CGM systems, particularly in low- and middle-income countries. This high price is a major barrier to the widespread use of CGMs and insulin pumps.

Segment Analysis

The global diabetes devices market is segmented based on product type, end-user and region.

Product Type:

The blood glucose monitoring devices segment is expected to dominate the diabetes devices market share

Blood glucose monitoring is fundamental to diabetes management. Both Type 1 and Type 2 diabetes require regular monitoring of blood glucose levels to avoid complications such as hypoglycemia, hyperglycemia and long-term damage to organs. Blood glucose monitoring devices, particularly self-monitoring blood glucose meters, are essential because they allow patients to track their glucose levels multiple times a day, ensuring more effective and personalized management of their condition.

There has been a significant shift towards home-based healthcare and self-care in diabetes management. With rising diabetes prevalence and increasing awareness, more patients are managing their diabetes at home, which has increased the demand for affordable and easy-to-use glucose meters. For instance, products like Accu-Chek by Roche and OneTouch by LifeScan are among the most popular self monitoring devices worldwide. These meters have gained significant market traction because of their user-friendly designs, quick results and cost-effectiveness, allowing patients to easily manage their diabetes from home. For instance, in November 2024, Medtronic announced the U.S. Food and Drug Administration (FDA) clearance for its new InPen smartphone app and announced the launch of its new Smart MDI system. Smart MDI especially designed to provide real-time insights to users on multiple daily injection (MDI) therapy. It includes the InPen smart insulin pen, the InPen app and Medtronic's disposable, all-in-one Simplera continuous glucose monitor (CGM), which received U.S. Food and Drug Administration approval.

Additionally, in May 2024, Smart Meter introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The redesigned model, branded iGlucose Plus, has many unique, advanced features that disrupt the remote blood glucose monitoring market and improves access for millions of patients to highly accurate diabetes management technology.

Geographical Analysis

North America is expected to hold a significant position in the diabetes devices market share

North America, particularly the United States, has one of the highest rates of diabetes in the world. According to the Centers for Disease Control and Prevention (CDC), over 38.4 million people in the U.S. have diabetes, which represents around 11.6% of the population. The majority of these individuals rely on various diabetes devices, such as blood glucose monitors, insulin pumps and continuous glucose monitors, to manage their condition.

North America is home to many of the leading manufacturers of diabetes devices, such as Medtronic, Dexcom, Abbott, Roche and Johnson & Johnson. These companies heavily invest in research, development, and innovation in diabetes devices, leading to the launch of newer technologies like smart insulin pumps, continuous glucose monitoring systems and closed-loop systems. For instance, in July 2024, Roche received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy.

Additionally, in August 2024, Abbott revealed a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

Asia-Pacific is growing at the fastest pace in the diabetes devices market

The Asia-Pacific region has seen a dramatic increase in diabetes prevalence due to lifestyle changes such as poor diet, sedentary habits and urbanization. According to the National Institute of Health, more than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined. The Western Pacific, the world's most populous region, has more than 138.2 million people with diabetes and the number may rise to 201.8 million by 2035. The increasing diabetes burden is one of the key drivers of the high demand for diabetes devices.

The adoption of advanced diabetes management devices, including continuous glucose monitoring systems (CGMs), insulin pumps and smart insulin pens, is growing in the APAC region. These technologies are providing better accuracy, convenience and ease of use, which appeal to both healthcare providers and patients.

For instance, in November 2024, Beurer India Pvt. Ltd. launched the GL 22 Blood Glucose Monitor, the launch marks Beurer's commitment to providing innovative and user-friendly health monitoring solutions tailored for the Indian market, aligning with its ambitious expansion plans across the country. The device features comprehensive monitoring capabilities, including average readings for 7, 14, 30, and 90 days, offering crucial insights into blood glucose trends. These features closely align with HbA1c levels, a critical marker for long-term blood sugar control, ensuring users and healthcare providers can manage diabetes more effectively.

Competitive Landscape

The major global players in the diabetes devices market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc, Terumo Corporation, B. Braun SE, Insulet Corporation, Nipro Corporation, Johnson & Johnson Services, Inc., Senseonics, Inc., Tandem Diabetes Care, Inc. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global diabetes devices market report delivers a detailed analysis with 54 key tables, more than 43 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by End-User
• 2.5. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Prevalence of Diabetes and Novel Product Launches
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of the Devices
  • 3.1.3. Opportunity
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Diabetes Devices Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Blood Glucose Monitoring Devices*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Continuous Glucose Monitoring Devices
    • 5.2.3.1. Sensors
    • 5.2.3.2. Transmitters
    • 5.2.3.3. Receivers
  • 5.2.4. Self-Monitoring Devices
    • 5.2.4.1. Blood Glucose Meters
    • 5.2.4.2. Testing Strips
    • 5.2.4.3. Lancets
• 5.3. Insulin Delivery Devices
  • 5.3.1. Insulin Pumps
  • 5.3.2. Insulin Pens
  • 5.3.3. Insulin Syringes
  • 5.3.4. Others

6. Diabetes Devices Market, By End-User

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 6.1.2. Market Attractiveness Index, By End-User
• 6.2. Hospitals*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Specialty Clinics
• 6.4. Homecare Settings
• 6.5. Diagnostic Centers
• 6.6. Others

7. Diabetes Devices Market, By Regional Market Analysis and Growth Opportunities

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 7.1.2. Market Attractiveness Index, By Region
• 7.2. North America
  • 7.2.1. Introduction
  • 7.2.2. Key Region-Specific Dynamics
  • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.2.5.1. U.S.
    • 7.2.5.2. Canada
    • 7.2.5.3. Mexico
• 7.3. Europe
  • 7.3.1. Introduction
  • 7.3.2. Key Region-Specific Dynamics
  • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.3.5.1. Germany
    • 7.3.5.2. U.K.
    • 7.3.5.3. France
    • 7.3.5.4. Spain
    • 7.3.5.5. Italy
    • 7.3.5.6. Rest of Europe
• 7.4. South America
  • 7.4.1. Introduction
  • 7.4.2. Key Region-Specific Dynamics
  • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.4.5.1. Brazil
    • 7.4.5.2. Argentina
    • 7.4.5.3. Rest of South America
• 7.5. Asia-Pacific
  • 7.5.1. Introduction
  • 7.5.2. Key Region-Specific Dynamics
  • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.5.5.1. China
    • 7.5.5.2. India
    • 7.5.5.3. Japan
    • 7.5.5.4. South Korea
    • 7.5.5.5. Rest of Asia-Pacific
• 7.6. Middle East and Africa
  • 7.6.1. Introduction
  • 7.6.2. Key Region-Specific Dynamics
  • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8. Competitive Landscape and Market Positioning

• 8.1. Competitive Overview and Key Market Players
• 8.2. Market Share Analysis and Positioning Matrix
• 8.3. Strategic Partnerships, Mergers & Acquisitions
• 8.4. Key Developments in Product Portfolios and Innovations
• 8.5. Company Benchmarking

9. Company Profiles

• 9.1. F. Hoffmann-La Roche Ltd*
  • 9.1.1. Company Overview
  • 9.1.2. Product Portfolio and Description
  • 9.1.3. Financial Overview
  • 9.1.4. Key Developments
  • 9.1.5. SWOT Analysis
• 9.2. Abbott Laboratories
• 9.3. Medtronic plc
• 9.4. Terumo Corporation
• 9.5. B. Braun SE
• 9.6. Insulet Corporation
• 9.7. Nipro Corporation
• 9.8. Johnson & Johnson Services, Inc.
• 9.9. Senseonics, Inc.
• 9.10. Tandem Diabetes Care, Inc.

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

• 10.1. Data Collection Methods
• 10.2. Data Triangulation
• 10.3. Forecasting Techniques
• 10.4. Data Verification and Validation

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us